Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.

Abstract: A method for tracking users of a cellular communications network in which the network pages users according to registration messages received from the users. Within each location area of the network, the cells are assigned identities. The cells broadcast codes representative of those identities to the users. In a first preferred embodiment, the identities facilitate the computation, by the users, of distance traveled. Each user transmits a registration message only after traveling a certain distance. In a second preferred embodiment, neighboring cells have different identities. Each user transmits a registration message only after exceeding a threshold number of transits from one cell to another. In a third preferred embodiment, each cell is assigned a unique identity. Each user transmits registration messages periodically, but only if the cell in which the user is located has changed since the last registration transmission.

Abstract: A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method molecules denaturating a target molecule in the presence of presumptative antiaggregation molecules to prevent the target molecules from self-or induced-aggregation. The nonaggregated target molecule coupled to the anti-aggregation molecule is then tested for bioactivity.